瑞苏伐他汀对2型糖尿病大鼠心肌的保护作用及其机制

目的：探讨瑞苏伐他汀对2型糖尿病大鼠心肌病变的防治作用及其作用机制.方法：STZ注射诱导制备T2DM大鼠模型,成功模型随机分为对照组（B组,n=25）、瑞苏伐他汀组（C组,n=25）,并设正常对照组（A组,n=10）.于第14周末取大鼠心脏,称取心脏质量并计算心脏肥厚指数（HWI）,胶原容积分数（CVF）,电镜观察心肌超微结构; 应用免疫组化法检测过氧化物酶体激活物受体α（PPARα）在心肌组织中的表达.结果：B组大鼠表现出心肌病特征,HWI,CVF增加,电镜观察可见大鼠心肌纤维以变性坏死为主,肌丝纤维丢失,肌丝排列紊乱,间质胶原纤维增多,糖原、脂褐素沉积等病理改变,C组大鼠心肌病变较B组有所减轻,HWI,CVF下降,免疫组化图像分析显示,B组大鼠心肌PPARα蛋白表达比A组明显升高,C组大鼠PPARα蛋白表达比B组明显升高,差别均具有统计学意义（均P〈0.01）.结论：瑞苏伐他汀在调脂的基础上,通过提高心肌PPARα的表达,对T2DM的心肌病变具有保护作用.

Protective effects and the mechanism of Rosuvastatin on type 2 diabetic rats

AIM：To study the protective effects and the mechanism of Rosuvastatin on type 2 diabetic rats.METHODS：Type 2 diabetes mellitus（T2DM） rat model was copied by giving SD rats a low dose of STZ.T2DM rats were divided randomly into control group（group B,n=25）,Rosuvastatin group（group C,n=25）,normal group was build（group A,n=10）.At the end of 14 weeks,the HWI,CVF were detected,ultrastructure of left ventricle were observed with electron microscopes.The protein expression of PPARα in myocardium was detected by immunohistochemical staining.RESULTS：In group B,DCM hearts demonstrated diabetic cardiomyopathy phenotype,HWI and CVF were higher than that in group A,cardiac muscle degeneration,focal necrosis and region adipocytes infiltrating could be observed.Foregoing changes in group C rats were more relieved than those in group B rats.The protein expression of PPARα in myocardium showed that the IDP of PPARα in group B was higher than in group A rats and the IDP in group C rats was higher than that in group B rats（P0.01）.CONCLUSION：Rosuvastatin based on TC lowering,elicits benefitial effects on cardiovascular diseases by increasing PPARα expression.